SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors anticipate long-term Week 40 clinical data for their flagship candidate, sonelokimab, which is set to be presented at an upcoming dermatology conference. The community is heavily focused on the drug's potential to establish a 'best-in-class' profile for treating Hidradenitis Suppurativa, with active discussions revolving around institutional accumulation patterns, recent analyst upgrades, and persistent speculation regarding potential M&A interest from major pharmaceutical players.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is currently capturing significant market attention as traders monitor its price action following recent airdrop activity and major exchange listings, with the community actively debating whether it serves as a legitimate institutional-grade privacy solution or simply another speculative venture. Sentiment remains deeply divided, as some investors express confidence in the project's Cardano-linked utility and zero-knowledge proof technology, while others remain skeptical, citing concerns over decentralization, corporate influence, and perceived parallels to previous market cycles.

BlockDAG is a hybrid concept that combines features of both traditional blockchains and DAGs. It retains the benefits of DAGs, such as high scalability and faster transaction processing, while integrating the security and trust of blockchain consensus mechanisms. BlockDAG emerges as a groundbreaking solution, meticulously merging the strengths of both blockchain and DAG architectures. It leverages the robust security and decentralization of blockchains while incorporating the efficient, scalable transaction processing of DAGs. This strategic integration allows blockDAG to handle a significantly higher volume of transactions at faster speeds compared to traditional blockchains. By overcoming the inherent limitations of both technologies, blockDAG paves the way for a future where distributed ledgers can seamlessly scale to meet the ever-growing demands of the cryptocurrency and broader digital landscape.

BlockDAG

BlockDAG is currently facing intense scrutiny and widespread accusations of being a sophisticated scam, driven by severe community frustration over inaccessible tokens, failed claim processes, and suspicious exchange activity. Investors are actively debating the legitimacy of the project as they vent about missing balances, lack of functional contracts, and concerns that early access programs unfairly privilege insiders over retail participants.

Borr Drilling Ltd. engages in the provision of offshore drilling services to the oil and gas industry. It operates through Dayrate; and Integrated Well Services (IWS) segments. The Dayrate segment consists of rig charters and ancillary services. The IWS segment provides integrated well services through Opex and Akal. The company was founded by Tor Olav Trøim on August 8, 2016 and is headquartered in Hamilton, Bermuda.

Borr Drilling Ltd

Borr Drilling is capturing market attention as investors weigh the impact of recent contract expansions and a transition in executive leadership against persistent debt concerns. The community remains divided, with many traders actively accumulating shares based on potential upside in the offshore rig market, while others express caution regarding the company's long-term financial leverage.

iShares Trust - iShares MSCI India ETF

iShares MSCI India ETF

The iShares MSCI India ETF (INDA) is currently in focus as investors weigh the potential impact of looming U.S. reciprocal tariffs and geopolitical tensions against the nation's robust long-term growth story and ongoing trade deal negotiations. While market participants are actively discussing the risks of foreign equity outflows and currency volatility, many community members remain bullish on India's resilience and its strategic potential as a global manufacturing hub.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending as investors weigh persistent geopolitical uncertainty and fiscal policy concerns against the broader strength of U.S. markets. Community discourse remains heavily polarized, with many users debating the impact of ongoing administration conflicts on long-term portfolio stability and the relative merits of broad index-based strategies versus active trading.

Rio Tinto Plc engages in the exploration, mining, and processing of mineral resources. It operates through the following business segments: Iron Ore, Aluminium, Copper, and Minerals. The Iron Ore segment supplies iron ore mining and salt and gypsum production. The Aluminium segment produces bauxite, alumina and primary aluminum. The Copper segment offers gold, silver, molybdenum and other by-products. The Minerals includes businesses with products such as uranium, borates, salt and titanium dioxide feedstock together with coal operations. The Other Operations segment covers the curtailed Gove alumina refinery and Rio Tinto Marine operations. The company was founded in 1873 and is headquartered in London, the United Kingdom.

Rio Tinto plc - ADR

Rio Tinto plc

Rio Tinto is drawing significant investor attention due to the finalized acquisition of Arcadium Lithium and a strategic focus on expanding its U.S. copper footprint, highlighted by the fast-tracking of its Resolution Copper project. While the stock navigates iron ore price volatility and ongoing geopolitical trade concerns, the community remains bullish on its long-term commodity cycle prospects and its transition into critical battery minerals.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is currently a major focus for traders who are monitoring the development of its 11GW Project Matador campus, with significant community discourse revolving around the anticipated announcement of an anchor tenant. Investors are weighing high-conviction bullish cases involving institutional support and power infrastructure demands against concerns over stock volatility, ongoing class action headlines, and the need for definitive contract signings to validate the company's long-term valuation.

Honeywell International, Inc. is a software industrial company, which offers industry specific solutions to aerospace and automotive products and services. It operates through the following business segments: Aerospace Technologies, Industrial Automation, Building Automation, Energy and Sustainability Solutions, and Corporate and All Other. The company was founded by Albert M. Butz in 1906 and is headquartered in Charlotte, NC.

Honeywell International Inc

Honeywell International is gaining investor attention as it progresses with its strategic plan to split into three independent entitiesAerospace, Automation, and Advanced Materials (Solstice)aiming to unlock shareholder value similar to past industrial conglomerates. The stock is currently oscillating amid broader industrial sector volatility, while community discussion remains focused on the potential upside of these spin-offs and the long-term growth prospects of its majority-owned quantum computing subsidiary, Quantinuum.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is experiencing heightened investor attention and price volatility fueled by speculative anticipation of a potential buyout, specifically involving major shareholder Nestl. The community is actively debating whether current momentum signals a genuine strategic deal or a repeated market pump, with long-term investors tracking upcoming clinical data readouts as a potential catalyst to force a valuation floor or merger.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average   - What's Next?

Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell...

Cantor Fitzgerald Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX)

Cantor Fitzgerald began coverage on shares of Tenax Therapeutics in a research report on Tuesday. They set an "overweight" rating and a $35.00 target price on the stock...

Boothbay Fund Management LLC Purchases Shares of 352,206 Tenax Therapeutics, Inc. $TENX

Boothbay Fund Management LLC acquired a new position in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX - Free Report) in the third quarter, according to its most recent Form 13F filing with the...

Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Tuesday

Tenax Therapeutics (NASDAQ:TENX) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 24. (View Earnings Report at...

Guggenheim Issues Positive Forecast for Tenax Therapeutics (NASDAQ:TENX) Stock Price

Guggenheim raised their price target on shares of Tenax Therapeutics from $25.00 to $34.00 and gave the stock a "buy" rating in a report on Monday...

What is Lifesci Capital's Forecast for TENX Q1 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX - Free Report) - Equities researchers at Lifesci Capital issued their Q1 2026 earnings estimates for Tenax Therapeutics in a report released on Thursday, March...

Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the stock, MarketBeat.com reports. One...

Tenax Therapeutics (NASDAQ:TENX) Shares Cross Above 200 Day Moving Average - Here's What Happened

Tenax Therapeutics (NASDAQ:TENX) Share Price Passes Above 200 Day Moving Average - Here's Why...

Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

Tenax Therapeutics (NASDAQ:TENX) Share Price Crosses Above 200 Day Moving Average - What's Next...

Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference

Executives from Tenax Therapeutics (NASDAQ:TENX) outlined progress on the company's Phase III development program for levosimendan in pulmonary hypertension associated with heart failure with...

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Current Price	$14.90
Prev Close	$14.97
Open	$14.99
Dividend Yield	0.00%
50-Day Moving Average	$13.43
Beta	0.41
Avg. Volume	189,942.25
PE Ratio	-11.15

52-Week High	$18.38
52-Week Low	$4.63
Market Capitalization	$256.24M
EPS (Annual)	-$1.34
Price to Book	1.43
Revenue Per Employee	$0.00

TENX
Tenax Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest TENX News

TENXTenax Therapeutics Inc